Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02503332 · ClinicalTrials.gov registry record · Phase 2
Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy
A Phase 2 study, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 246
- Enrollment target
NCT02503332: Completed Phase 2 study, sponsored by Apellis Pharmaceuticals.
NCT02503332 is a Phase 2 study that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 246 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02503332, a Phase 2 study, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 246 participants
- Enrollment target
Study Summary
The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
Primary Outcome
The square root GA lesion size (i.e. transformed area of GA) was measured by FAF photographs. Baseline was defined as the last available, non-missing observation prior to first study drug administration.
Interventions
- DRUG Pegcetacoplan
- OTHER Sham Procedure
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 246 participants |
| Start Date | 2015-09-24 |
| Est. Completion | 2018-01-17 |
| Phase | Phase 2 |
What the finished NCT02503332 record still lists
NCT02503332 is an interventional study that assigns participants to a tested intervention. The registered 246 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (85% higher).
The record links to 0 conditions, and to 2 interventions - of which Pegcetacoplan is the first listed.
NCT02503332 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02503332 about?
NCT02503332 is a clinical study titled "Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy". The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).
What is the current status of trial NCT02503332?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 246 participants. The study started on 2015-09-24. Estimated completion is 2018-01-17.
What interventions are being tested in trial NCT02503332?
The interventions under investigation include: Pegcetacoplan (DRUG), Sham Procedure (OTHER).
Who is sponsoring clinical trial NCT02503332?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02503332's enrollment target sits among peer trials
246 234th of 2000 higher than 1,767 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04973605 · 246 participants · Phase 1
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- NCT06395168 · 246 participants · NA
Mayo Clinic Health System Northwest Wisconsin Integrated Maternal Postpartum Appointment Combination
- NCT07048769 · 246 participants · Phase 4
Paracervical Block for Pain Reduction in Saline Infusion Sonograms
- NCT07176650 · 246 participants · Phase 1
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI